Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.…
Nexstim (HEL: NXTMH) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 8.450 EUR on 20 November 2026, down 42.9% over 52 weeks. Its 52-week range is 7.890 EUR to 15.00 EUR: the price is 43.7% below the high and 7.1% above the low.
Its market capitalisation is 61.13M EUR.
Nexstim reports return on equity of 13.7%, an operating margin of 4.8% and revenue up 16.1% year over year.
It holds more cash than debt, a net cash position of 2.17M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 11.50 EUR is 36.1% above the current price.
No upcoming events tracked.